Targeted Medical Pharma IncOver The Counter Market:TRGM
- LAST PRICE0.0001
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0001
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Targeted Medical Pharma Inc | 3.0K | 0.0x | --- |
Parnell Pharmaceuticals Holdings Ltd | 20.0 | 0.0x | --- |
Vapor Group Inc | 27.3K | 0.0x | --- |
Orexo AB | 52.8M | -4.1x | --- |
RXElite Inc | 120.0 | 0.0x | --- |
Scorpius Holdings Inc | 6.1M | -0.1x | --- |
Company Information
Targeted Medical Pharma, Inc. is a medical nutrition company. The Company is engaged in developing amino acid based medical foods and other oral nutrition products for the long-term management of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep, respiratory disorders, allergies and cognitive disorders. It manufactures eight amino acid based medical foods along with the dietary supplements, which include Grotrexa, AppTrim, Hypertensa Advanced and Clearwayz. Its Targeted Cellular Technology is a patented formulation that allows reduced concentrations of amino acids and other ingredients in the milligram range to stimulate the production of neurotransmitters to treat the nutritional deficiencies associated with certain diseases and conditions. The Company’s medical food brands include Theramine, Trepadone, Percura, GABAdone, Sentra PM, AppTrim-D and Sentra AM.
Contact Information
- Headquarters
- 2980 Beverly Glen Circle, Suite 301LOS ANGELES, CA, United States 90077
- Phone
- 310-474-9809
- Fax
- 310-531-7089
Executives
- Non-Executive Chairman of the Board, Director
- Kerry Weems
- Interim Chief Executive Officer, Director
- Marcus Charuvastra
- Executive Vice President - Foreign Sales, Director
- Kim Giffoni
- Chief Technology Officer
- Douglas Gintz
- Independent Director
- Maurice DeWald
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0K |
|---|---|
Revenue (TTM) | $5.3M |
Shares Outstanding | 30.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.11 |
Book Value | $-0.47 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -38.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
